Details of the Drug

General Information of Drug (ID: DMSREPX)

Drug Name

Levobetaxolol

Synonyms

Levobetaxolol [INN]; Betaxon (TN); (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; (2S)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol; (2s)-1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(isopropylamino)propan-2-ol; (S)-(-)-Betaxolol; (S)-1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; (S)-Betaxolol

Indication

Disease Entry	ICD 11	Status	REF
Chronic open-angle glaucoma	9C61.0	Approved	[1]
Ocular hypertension	9C61.01	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Cardiotonic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

307.4

Logarithm of the Partition Coefficient (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h []
Half-life: The concentration or amount of drug in body reduced by one-half in 20 hours []

Chemical Identifiers

Formula: C18H29NO3
IUPAC Name: (2S)-1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
Canonical SMILES: CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O
InChI: InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3/t17-/m0/s1
InChIKey: NWIUTZDMDHAVTP-KRWDZBQOSA-N

Cross-matching ID

PubChem CID: 60657
ChEBI ID: CHEBI:59254
CAS Number: 93221-48-8
DrugBank ID: DB09351
TTD ID: D0A6CQ
INTEDE ID: DR0932

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Levobetaxolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Levobetaxolol and Atracurium.	Corneal disease [9A76-9A78]	[5]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Levobetaxolol and Siponimod.	Multiple sclerosis [8A40]	[6]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Levobetaxolol and Ozanimod.	Multiple sclerosis [8A40]	[7]
-----------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Levobetaxolol FDA Label
3	Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9.
4	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
5	Harrah MD, Way WL, Katzung BG "The interaction of d-tubocurarine with antiarrhythmic drugs." Anesthesiology 33 (1970): 406-10. [PMID: 5512329]
6	Cerner Multum, Inc. "Australian Product Information.".
7	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.